BioCentury
ARTICLE | Company News

EPO rejects Soliris patent, schedules oral hearing

May 8, 2018 8:39 PM UTC

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said the European Patent Office has rejected a patent that would extend exclusivity through 2027 for rare disease drug Soliris eculizumab. An oral hearing has been scheduled for Feb. 5, 2019.

The company told BioCentury that the patent process in Europe "involves several rounds" and that the issues raised by the European Patent Office are similar to those raised in the U.S. and Japan, where corresponding patents have already been issued. ...

BCIQ Company Profiles

Alexion Pharmaceuticals Inc.

BCIQ Target Profiles

Complement 5 (C5)